Top 10 Tasimelteon (Hetlioz) Generic Manufacturers in Australia
The pharmaceutical market in Australia is evolving, particularly with the increasing demand for generic medications, which often provide cost-effective alternatives to branded drugs. Tasimelteon, marketed under the brand name Hetlioz, is a drug primarily used for the treatment of Non-24-Hour Sleep-Wake Disorder. The Australian pharmaceutical market was valued at approximately AUD 25 billion in 2021, with generics contributing significantly to this figure. As of 2023, the generic drug segment is projected to grow at a compound annual growth rate (CAGR) of 6.3% through 2025, driven by an increasing prevalence of sleep disorders and the subsequent demand for affordable treatment options.
1. Apotex Pty Ltd
Apotex is one of the largest generic pharmaceutical companies in Australia, with a significant market share of around 15%. The company produces a wide range of generic medications, including Tasimelteon, which has been well-received due to its affordability and effectiveness. Apotex’s production capacity is approximately 2 billion doses annually.
2. Mylan Australia
Mylan, now part of Viatris, is a global leader in the generic pharmaceutical market, holding a market share of about 10% in Australia. Mylan produces Tasimelteon generics that cater to the growing demand for affordable sleep disorder medications. The company has a production volume exceeding 1 billion units per year, contributing significantly to the availability of generics in the Australian market.
3. Sandoz Australia
As a division of Novartis, Sandoz is a major player in the generic pharmaceuticals sector, with a focus on high-quality production. With a market share of around 8%, Sandoz offers a Tasimelteon generic that has gained traction among healthcare professionals. The company’s production capabilities allow it to produce over 1.5 billion doses annually.
4. Sigma Pharmaceuticals
Sigma Pharmaceuticals is one of Australia’s leading generic manufacturers, with a market share of approximately 7%. The company has developed a Tasimelteon generic that is both accessible and effective for patients. Sigma’s production output is estimated to be around 500 million units per year, reflecting its robust manufacturing capabilities.
5. Alphapharm
Part of the Mylan family, Alphapharm is a well-known generic pharmaceutical manufacturer in Australia. The company has a market share of about 6%, producing a variety of generic drugs, including Tasimelteon. Alphapharm’s annual production capacity is estimated at 400 million doses, ensuring steady supply to the market.
6. Fresenius Kabi Australia
Fresenius Kabi specializes in generic injectable medications, holding a market share of approximately 5%. The company produces a range of products, including Tasimelteon, which are crucial for patients with sleep disorders. With a production volume of around 300 million units, Fresenius Kabi plays a key role in the Australian pharmaceutical landscape.
7. Ranbaxy Australia (Sun Pharmaceutical Industries)
Ranbaxy, now a part of Sun Pharmaceutical Industries, is a prominent player in the Australian generics market, with a market share of about 4%. The company produces a Tasimelteon generic that is favored for its cost-effectiveness. Ranbaxy’s annual production capacity is approximately 250 million units, contributing to the availability of essential medications.
8. Generic Health
Generic Health is known for its focus on quality and affordability in the Australian market, holding a market share of around 3%. The company has developed a generic version of Tasimelteon that is well-regarded for its therapeutic efficacy. Generic Health has an estimated production output of 200 million doses per year.
9. Baxter Healthcare
Baxter Healthcare is a notable manufacturer of generic medications, particularly in the injectable segment, with a market share of about 3%. They offer a Tasimelteon generic that supports the treatment of sleep disorders effectively. Baxter’s production capabilities are robust, with an annual output of approximately 150 million units.
10. Biogenerics
Biogenerics focuses on the development of biosimilars and generics, with a smaller market share of around 2%. Their Tasimelteon generic is gaining traction among healthcare providers and patients alike. Biogenerics produces approximately 100 million doses annually, addressing the growing demand for affordable treatment options.
Insights
The generics market in Australia is poised for significant growth, with the increasing prevalence of sleep disorders driving demand for medications like Tasimelteon. As of 2023, the generic segment is expected to reach a market size of AUD 20 billion by 2025, with Tasimelteon generics contributing to this growth due to their affordability and accessibility. Major manufacturers are expanding their production capabilities to meet rising consumer needs, highlighting the importance of strategic partnerships and innovative approaches in the pharmaceutical landscape.
Related Analysis: View Previous Industry Report
